A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
← catalyst calendarSponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With Suzhou Yasheng Pharmaceutical Co., Ltd..
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
80estimated
Sites
4
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-07-04 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2019-06-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- EGFR Positive Non-small Cell Lung Cancer
Interventions
- Drug: APG-1252 — also filed as APG-1252 for injection
- Drug: Osimertinib Mesylate Tablets — also filed as AZD9291
Primary outcomes
what the primary-completion date above is the date OFMaximum Tolerated Dose (MTD)
measured 21 days
Recommended Phase 2 dose (RP2D)
measured 21 days
Publications
- PMID 42442920 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed